Summary
Elevance Health, Inc. filed an 8-K on January 24, 2024, to report its financial results for the quarter ended December 31, 2023. The filing primarily consists of a press release detailing these results, which is furnished as an exhibit. Investors should note that this information is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, meaning it carries a different legal weight than a formally filed financial statement. The press release contains forward-looking statements that provide management's expectations for future financial performance and operational plans. Investors are cautioned to consider these statements in light of the numerous risks and uncertainties outlined in the filing, which could lead to material differences between projected and actual results. These risks encompass various factors, including healthcare cost trends, regulatory changes, operational disruptions, competitive pressures, and potential litigation.
Key Highlights
- 1Elevance Health released its Q4 2023 financial results via an 8-K filing on January 24, 2024.
- 2The primary content of the 8-K is a press release containing the financial results for the quarter ended December 31, 2023.
- 3Information furnished in this 8-K is not considered 'filed' for the purpose of Section 18 of the Securities Exchange Act.
- 4The filing includes standard forward-looking statements regarding future performance, projections, and plans.
- 5Investors are cautioned about significant risks and uncertainties that could impact future results, as detailed in the filing.
- 6Key risk factors mentioned include healthcare cost trends, regulatory impacts, operational and IT disruptions, and competitive pressures.
- 7The filing also notes risks related to government programs (Medicare/Medicaid), quality ratings, litigation, and potential cyber security incidents.